THYROID EYE DISEASE
Clinical trials for THYROID EYE DISEASE explained in plain language.
Never miss a new study
Get alerted when new THYROID EYE DISEASE trials appear
Sign up with your email to follow new studies for THYROID EYE DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to calm swollen eyes in thyroid disease patients
Disease control OngoingThis study tests an experimental drug called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the drug can reduce eye bulging over 24 weeks. Participants receive the drug …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control OngoingThis phase 3 trial tests an investigational drug called VRDN-003 in 204 people with chronic thyroid eye disease (TED). The drug is given as a shot under the skin and aims to reduce eye bulging and other symptoms. Participants are randomly assigned to receive either VRDN-003 or a …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising drug may reduce eye bulging in thyroid disease
Disease control OngoingThis study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. Participants receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters over 24 weeks. T…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug aims to reduce bulging eyes in thyroid disease
Disease control OngoingThis Phase 3 trial tests satralizumab, a drug that blocks IL-6, in 131 people with moderate-to-severe thyroid eye disease. The main goal is to see if it reduces eye bulging by at least 2 mm after 24 weeks. Participants receive either satralizumab or placebo injections, and resear…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New injection every 8 weeks shows promise for thyroid eye disease
Disease control OngoingThis study tests a drug called TOUR006 in 79 people with active thyroid eye disease, a condition that causes eye bulging and inflammation. Participants receive either a low dose, high dose, or placebo injection every 8 weeks. The main goal is to see if the drug can reduce eye bul…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE2 • Sponsor: Tourmaline Bio, Inc., a Novartis Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot could ease bulging eyes in thyroid disease
Disease control OngoingThis Phase 3 trial tests an investigational drug called VRDN-003 for active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The study involves 132 adults with moderate to severe symptoms. Participants receive either VRDN-003 or a placebo as a sh…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New shot could ease bulging eyes from thyroid disease
Disease control OngoingThis phase 3 trial tests an injectable drug called teprotumumab for people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. About 89 adults will receive either the drug or a placebo injection to see if it reduces eye bulging …
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC